Press Release
November 17, 2017

Alnylam Pharmaceuticals Closes $805 Million Public Offering

The Life Sciences team advised Alnylam Pharmaceuticals [NASDAQ: ALNY] on its public offering totaling $805 million in gross proceeds from the sale of 6,440,000 shares of common stock at a price of $125.00 per share, which included the full exercise of the underwriters’ option to purchase additional shares.
Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic and hepatic infectious diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.
The Goodwin team was led by partners Mitch Bloom and Gregg Katz and included associates Will Goldberg and Chloe Pletner.